TWI819995B - 以加波沙朵（ｇａｂｏｘａｄｏｌ）治療發育障礙的方法 - Google Patents

以加波沙朵（ｇａｂｏｘａｄｏｌ）治療發育障礙的方法 Download PDF

Info

Publication number
TWI819995B
TWI819995B TW105122538A TW105122538A TWI819995B TW I819995 B TWI819995 B TW I819995B TW 105122538 A TW105122538 A TW 105122538A TW 105122538 A TW105122538 A TW 105122538A TW I819995 B TWI819995 B TW I819995B
Authority
TW
Taiwan
Prior art keywords
hours
gaboxadol
pharmaceutical composition
pharmaceutically acceptable
patient
Prior art date
Application number
TW105122538A
Other languages
English (en)
Chinese (zh)
Other versions
TW201707700A (zh
Inventor
馬修 杜陵
Original Assignee
美商歐維得治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商歐維得治療公司 filed Critical 美商歐維得治療公司
Publication of TW201707700A publication Critical patent/TW201707700A/zh
Application granted granted Critical
Publication of TWI819995B publication Critical patent/TWI819995B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW105122538A 2015-07-17 2016-07-15 以加波沙朵（ｇａｂｏｘａｄｏｌ）治療發育障礙的方法 TWI819995B (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201562193717P 2015-07-17 2015-07-17
US62/193,717 2015-07-17
US201562207595P 2015-08-20 2015-08-20
US62/207,595 2015-08-20
US201662332567P 2016-05-06 2016-05-06
US62/332,567 2016-05-06
US201662346763P 2016-06-07 2016-06-07
US62/346,763 2016-06-07
US15/209,862 US20170014393A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol
US15/209,862 2016-07-14

Publications (2)

Publication Number Publication Date
TW201707700A TW201707700A (zh) 2017-03-01
TWI819995B true TWI819995B (zh) 2023-11-01

Family

ID=57774846

Family Applications (2)

Application Number Title Priority Date Filing Date
TW105122538A TWI819995B (zh) 2015-07-17 2016-07-15 以加波沙朵（ｇａｂｏｘａｄｏｌ）治療發育障礙的方法
TW112110413A TW202325293A (zh) 2015-07-17 2016-07-15 以加波沙朵(gaboxadol)治療發育障礙的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112110413A TW202325293A (zh) 2015-07-17 2016-07-15 以加波沙朵(gaboxadol)治療發育障礙的方法

Country Status (17)

Country Link
US (8) US20170014393A1 (enExample)
EP (2) EP3324961B1 (enExample)
JP (3) JP2018520189A (enExample)
KR (2) KR20180031721A (enExample)
CN (2) CN108024997A (enExample)
AU (2) AU2016295138B2 (enExample)
BR (1) BR112018000933A2 (enExample)
CA (1) CA2992734A1 (enExample)
CL (1) CL2018000142A1 (enExample)
CO (1) CO2018000375A2 (enExample)
ES (1) ES3021189T3 (enExample)
HK (1) HK1250951A1 (enExample)
IL (2) IL256912B2 (enExample)
MX (2) MX391708B (enExample)
PE (2) PE20190338A1 (enExample)
TW (2) TWI819995B (enExample)
WO (1) WO2017015049A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017516868A (ja) 2014-06-06 2017-06-22 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 持続性抑制を増加させ、二次性不眠症を治療する方法
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
EP3648762A4 (en) 2017-08-04 2021-03-24 Ovid Therapeutics, Inc. USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED DISEASES
WO2019098630A1 (ko) * 2017-11-14 2019-05-23 에스케이바이오팜 주식회사 취약 x 증후군, 엔젤만 증후군 또는 렛 증후군을 포함하는 발달 장애의 경감 또는 치료를 위한 카바메이트 화합물의 용도
WO2019241624A1 (en) * 2018-06-14 2019-12-19 Ovid Therapeutics Inc. Use of mir-92a or mir-145 in the treatment of angelman syndrome
EP3823619A4 (en) * 2018-08-22 2021-11-17 Ovid Therapeutics Inc. USE OF GABOXADOL FOR TREATMENT OF GIOMETAL TRACT DISORDERS AND ASTHMA
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
GB2594616A (en) 2018-11-21 2021-11-03 Certego Therapeutics Inc Gaboxadol for reducing risk of suicide and rapid relief of depression
JP2022511755A (ja) * 2018-11-21 2022-02-01 セルテゴ セラピューティクス インコーポレイテッド 精神障害の治療のためのガボキサドールとリチウムとの組み合わせ
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
JP7749169B2 (ja) * 2019-06-07 2025-10-06 クヴァトリス セラピューティクス， インコーポレイテッド 中枢神経系障害を処置するための組成物および方法
CN114173765A (zh) * 2019-07-15 2022-03-11 奥维德医疗公司 用于治疗性治疗的包含加波沙朵的药物制剂
CN114786669A (zh) * 2019-12-18 2022-07-22 奥维德医疗公司 用于1p36缺失综合征的治疗性治疗的加波沙朵
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102137667A (zh) * 2008-09-01 2011-07-27 H.隆德贝克有限公司 包含加波沙朵和patl或oat抑制剂的药物组合物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
ATE474572T1 (de) * 2000-11-30 2010-08-15 Novodermix Internat Ltd Heilung von wunden
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
WO2002094225A1 (en) 2001-05-21 2002-11-28 H. Lundbeck A/S Granular preparations of gaboxadol
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
EP1641456B1 (en) 2003-06-25 2010-03-03 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
EP1663218A1 (en) 2003-09-10 2006-06-07 MERCK SHARP & DOHME LTD. Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
WO2005063248A1 (en) 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
KR20070010136A (ko) * 2004-04-02 2007-01-22 하. 룬트벡 아크티에 셀스카브 가복사돌을 이용한 손상된 호흡 기능의 치료
AU2005229493A1 (en) 2004-04-02 2005-10-13 H. Lundbeck A/S Treatment of impaired respiratory function with gaboxadol
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
EP2314289A1 (en) * 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
HUE032743T2 (en) * 2006-11-22 2017-10-30 Clinical Res Ass Llc A method for treating Down syndrome, fragilis X syndrome and autism
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
US20090269795A1 (en) 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
US20100286762A1 (en) 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
CN102147667A (zh) 2010-02-08 2011-08-10 深圳富泰宏精密工业有限公司 触控笔
EP2621282B1 (en) 2010-09-28 2020-04-15 The Regents of The University of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2012075286A2 (en) 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US9480695B2 (en) 2011-09-29 2016-11-01 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
EP3108876A1 (en) 2011-10-13 2016-12-28 Jaleva Pharmaceuticals LLC Methods and compositions for rapid transbuccal delivery of active agents
EP4335505A3 (en) * 2012-11-30 2024-06-05 The Regents of The University of California Anticonvulsant activity of steroids
US20150313913A1 (en) 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
JP2017516868A (ja) * 2014-06-06 2017-06-22 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 持続性抑制を増加させ、二次性不眠症を治療する方法
US9802945B2 (en) 2014-06-12 2017-10-31 Pfizer Limited Imidazopyridazine derivatives as modulators of the GABAA receptor activity
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
MX394213B (es) 2015-08-11 2025-03-24 Ovid Therapeutics Inc Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos.
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
WO2017070680A1 (en) 2015-10-22 2017-04-27 Cavion Llc Methods for treating angelman syndrome and related disorders
CA3025473A1 (en) 2016-05-26 2017-11-30 Ovid Therapeutics Inc. Methods of treating behavioral syndromes using pipradrol
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
AU2017363598A1 (en) 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102137667A (zh) * 2008-09-01 2011-07-27 H.隆德贝克有限公司 包含加波沙朵和patl或oat抑制剂的药物组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 K EGAWA, et al., "Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman Syndrome", Sci Transl Med, 2012, 4(163)： 163ra157.; *
期刊 R LOZANO, et al., "Modulation of the GABAergic pathway for the treatment of fragile X syndrome", Neuropsychiatric Disease and Treatment, 2014, 10： 1769~1779. *

Also Published As

Publication number Publication date
JP2018520189A (ja) 2018-07-26
PE20190338A1 (es) 2019-03-07
EP4541420A2 (en) 2025-04-23
CA2992734A1 (en) 2017-01-26
TW201707700A (zh) 2017-03-01
CN116531370A (zh) 2023-08-04
US20180338960A1 (en) 2018-11-29
AU2016295138A1 (en) 2018-02-08
CL2018000142A1 (es) 2018-07-13
AU2016295138B2 (en) 2021-11-04
HK1250951A1 (zh) 2019-01-18
AU2021250862A1 (en) 2021-11-04
MX2018000745A (es) 2018-08-15
US20190321342A1 (en) 2019-10-24
PE20230735A1 (es) 2023-05-03
CN108024997A (zh) 2018-05-11
EP3324961A4 (en) 2019-03-13
JP2021130687A (ja) 2021-09-09
EP4541420A3 (en) 2025-06-25
KR20180031721A (ko) 2018-03-28
BR112018000933A2 (en) 2018-09-04
US20170014393A1 (en) 2017-01-19
US12465597B2 (en) 2025-11-11
EP3324961A1 (en) 2018-05-30
US20190255027A1 (en) 2019-08-22
US11096929B2 (en) 2021-08-24
US20180098974A1 (en) 2018-04-12
CO2018000375A2 (es) 2018-04-19
IL256912B2 (en) 2024-01-01
MX2022004734A (es) 2022-05-13
JP2023103375A (ja) 2023-07-26
IL305342B1 (en) 2026-02-01
KR20240160666A (ko) 2024-11-11
AU2021250862B2 (en) 2023-11-09
MX391708B (es) 2025-03-21
US20210030727A1 (en) 2021-02-04
EP3324961B1 (en) 2025-03-19
WO2017015049A1 (en) 2017-01-26
IL256912B1 (en) 2023-09-01
US20230071127A1 (en) 2023-03-09
IL256912A (en) 2018-03-29
TW202325293A (zh) 2023-07-01
IL305342A (en) 2023-10-01
ES3021189T3 (en) 2025-05-26
US20190117632A1 (en) 2019-04-25
EP3324961C0 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
TWI819995B (zh) 以加波沙朵（ｇａｂｏｘａｄｏｌ）治療發育障礙的方法
US10426746B2 (en) Methods of treating developmental disorders with biguanides
US20190328719A1 (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine
HK40097170A (zh) 用加波沙朵治疗发育障碍的方法